{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:56:29Z","timestamp":1790945789096,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) associated osteoporosis leads to an increased risk of bone fracture in patients with CKD. Evidence on the efficacy and safety of anti\u2010osteoporotic medications is limited for this group. This systematic review aimed to examine the efficacy and safety of anabolic parathyroid hormone (PTH) treatment in patients with CKD Stages 4\u20135D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE and ClinicalTrials.gov were searched systematically for randomized controlled trials (RCTs) investigating teriparatide, natpara, or abaloparatide in adult patients with CKD Stages 4\u20135D, including kidney transplant recipients. The primary outcome was the change in bone mineral density (BMD) during follow\u2010up measured at the lumbar spine (LS), femoral neck (FN) and total hip (TH). The secondary outcomes included bone turnover markers, fractures, histomorphometric results from bone biopsies and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two RCTs were included. A subgroup analysis of patients with CKD Stage 4 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) showed that teriparatide improved BMD at the LS and FN. Another trial (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200961) in CKD Stage 5D showed significant BMD improvement at the TH compared to the control group. AEs were observed with higher frequency in the teriparatide\u2010treated group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with teriparatide seems to improve BMD in patients with CKD Stages 4\u20135D, but evidence on efficacy and safety is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>PROSPERO: CRD42024527086<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcpt.70293","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:31:31Z","timestamp":1790944291000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review"],"prefix":"10.1111","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7612-1468","authenticated-orcid":false,"given":"Huriye Seyma","family":"Kafa","sequence":"first","affiliation":[{"name":"Department of Nephrology Copenhagen University Hospital \u2013 Herlev and Gentofte Hospital  Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-7513","authenticated-orcid":false,"given":"Sabina Chaudhary","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Nephrology Copenhagen University Hospital \u2013 Herlev and Gentofte Hospital  Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Nephrology Copenhagen University Hospital \u2013 Herlev and Gentofte Hospital  Herlev Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr317"},{"issue":"6","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","article-title":"Management of Osteoporosis in CKD","volume":"13","author":"Khairallah P.","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"108","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00223-020-00786-0","article-title":"Traditional and Non\u2010Traditional Risk Factors for Osteoporosis in CKD","volume":"4","author":"J\u00f8rgensen H. S.","year":"2021","journal-title":"Calcified Tissue International"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta\u2010Analysis of How Well Measures of Bone Mineral Density Predict Occurrence of Osteoporotic Fractures","volume":"312","author":"Marshall D.","year":"1996","journal-title":"BMJ"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.07.019"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S53489"},{"issue":"19","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of Parathyroid Hormone (1\u201334) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis","volume":"344","author":"Neer R.","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of Recombinant Human Parathyroid Hormone (1\u201384) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women With Osteoporosis: A Randomized Trial","volume":"146","author":"Greenspan S. L.","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136"},{"issue":"113","key":"e_1_2_13_12_1","first-page":"S90","article-title":"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2010MBD Work Group","year":"2009","journal-title":"Kidney International"},{"issue":"41","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nefroe.2021.11.014","article-title":"Hyporesponsiveness or Resistance to the Action of Parathyroid Hormone in Chronic Kidney Disease","volume":"5","author":"Bover J.","year":"2021","journal-title":"Nefrologia (English Edition)"},{"issue":"3","key":"e_1_2_13_14_1","first-page":"160","article-title":"Calcific Uremic Arteriolopathy in Association With Low Turnover Uremic Bone Disease","volume":"52","author":"Mawad H. W.","year":"1999","journal-title":"Clinical Nephrology"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_13_16_1","unstructured":"\u201cPROSPERO \u201d accessed September 14 2024 [Online] cited September 14 2024 https:\/\/www.crd.york.ac.uk\/prospero\/."},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70159","article-title":"BCPT 2026 Policy for Experimental and Clinical Studies","volume":"137","author":"Tveden\u2010Nyborg P.","year":"2026","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"e_1_2_13_18_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 6.4, Updated August 2023)","author":"Lefebvre C.","year":"2023"},{"key":"e_1_2_13_19_1","unstructured":"Covidence \u201cCovidence Platform [Internet] \u201dhttps:\/\/support.covidence.org\/help."},{"key":"e_1_2_13_20_1","unstructured":"J.Higgins J.Savovi\u0107 M. J.Page andJ. A.Sterne \u201cRevised Cochrane Risk of Bias Tool for Randomized Trials (RoB 2.0) \u201d (2016)."},{"key":"e_1_2_13_21_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 6.4)","author":"Sch\u00fcnemann H. J.","year":"2013"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010006\u20100189\u20108"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN110993"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000316708"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S120175"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341864"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010015\u20103377\u20106"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744\u20109987.12867"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010021\u201002735\u20109"},{"issue":"2","key":"e_1_2_13_30_1","first-page":"166","article-title":"Pharmacokinetics of Teriparatide After Subcutaneous Administration to Volunteers With Renal Failure: A Pilot Study","volume":"52","author":"Hiromitsu I.","year":"2013","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014\u20103718"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.12.041"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1656955"},{"issue":"7","key":"e_1_2_13_34_1","article-title":"Pharmacological Interventions Versus Placebo, No Treatment or Usual Care for Osteoporosis in People With chronic Kidney Disease Stages 3\u20105D","volume":"2021","author":"Hara T.","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.70293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:31:35Z","timestamp":1790944295000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.70293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/bcpt.70293"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.70293","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"2026-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70293"}}